Table 1 Clinical data of patients with a healthcare-associated colonization or infection by an Extended-Spectrum Beta-Lactamase (ESBL) producing microorganism

Demographic characteristics:

   Male sex

56 (54)

   Age: median; years (inter-quartile range)

71 (62-79)

   Patients over 65 years

67 (64)

   Nursing home residents, n (% of patients over 65 years)

16 (24)

Proportion of ambulatory or hospitalized patients:

   Outpatients

15 (14)

   Inpatients

89 (86)

Co-morbidities:

   CIRS*: mean global score ± SD (inter-quartile range)

10.5 ± 3.9 (8-13)

   CIRS: mean nr of different categories ± SD (inter-quartile range)

5.2 ± 2.0 (4-7)

   Mean Norton Index ± SD;/20 points (inter-quartile range)

14.8 ± 3.6 (12-18)

   Diabetes Mellitus

24 (23)

   Chronic renal insufficiency

24 (23)

   Heart failure

13 (12.5)

   Severe chronic respiratory disease

17 (16)

   Cirrhoses

3 (3)

   Haematological malignancies

8 (8)

   Pressure ulcers

16 (15)

   Urinary catheters

38 (37)

   Wounds

34 (33)

   PEG** or tracheotomy

7 (7)

Medications:

   Proton pump inhibitors

34 (33)

   Histamine₂ receptor antagonist

25 (24)

   Number of patients previously exposed to antibiotics:

60 (58)

   Mean antibiotic use ± SD (inter-quartile range)

2 ± 1.5 (1-3)

Clinical infection due to an ESBL microorganism:

68 (65)

   Urinary tract infection

38 (55.9)

   Respiratory tract infection

18 (26.5)

   Bloodstream infection

6 (8.8)

   Others

6 (8.8)

Simple ESBL carriers (colonization):

36 (35)

Previous known MRSA carriage:

9 (9)

Contact with health care system:

   Previous hospitalization within 1 year

68 (65)

   Multiple contacts within 1 year

71 (68)

   Admission to ICU^§ during current hospitalization

30 (29)

Median overall LOS ^§§ , days (inter-quartile range):

23 (13-39)

Proportion with a long LOS (≥ 8 days)

77 (87)

Number of death:

12 (12)